Loading stock data…
$1.92-0.03 (-1.55%)
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.
Can-Fite BioPharma Ltd. in the Healthcare sector is trading at $1.92 with a market capitalization of $6M. Wall Street consensus targets $8.00 (1 analysts), implying a +316.7% move over the next 12 months. The stock is currently near its 52-week low of $1.90, remaining 42.7% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $155,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | -$1.83M |
| Net Income | — | — | — | — | -$1.65M |
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead dru...